124 related articles for article (PubMed ID: 11390329)
1. Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women.
Barinas-Mitchell E; Cushman M; Meilahn EN; Tracy RP; Kuller LH
Am J Epidemiol; 2001 Jun; 153(11):1094-101. PubMed ID: 11390329
[TBL] [Abstract][Full Text] [Related]
2. Body composition modulates the effects of hormone replacement therapy on growth hormone and insulin-like growth factor-I levels in postmenopausal women.
Figueroa A; Going SB; Milliken LA; Blew R; Sharp S; Lohman TG
Gynecol Obstet Invest; 2002; 54(4):201-6. PubMed ID: 12592062
[TBL] [Abstract][Full Text] [Related]
3. Leptin in postmenopausal women: influence of hormone therapy, insulin, and fat distribution.
Gower BA; Nagy TR; Goran MI; Smith A; Kent E
J Clin Endocrinol Metab; 2000 May; 85(5):1770-5. PubMed ID: 10843150
[TBL] [Abstract][Full Text] [Related]
4. Relationship between hormone replacement therapy use with body fat distribution and insulin sensitivity in obese postmenopausal women.
Sites CK; Brochu M; Tchernof A; Poehlman ET
Metabolism; 2001 Jul; 50(7):835-40. PubMed ID: 11436191
[TBL] [Abstract][Full Text] [Related]
5. Physical activity, body fat, and serum C-reactive protein in postmenopausal women with and without hormone replacement.
Manns PJ; Williams DP; Snow CM; Wander RC
Am J Hum Biol; 2003; 15(1):91-100. PubMed ID: 12552583
[TBL] [Abstract][Full Text] [Related]
6. Hormone replacement therapy and increased plasma concentration of C-reactive protein.
Ridker PM; Hennekens CH; Rifai N; Buring JE; Manson JE
Circulation; 1999 Aug; 100(7):713-6. PubMed ID: 10449692
[TBL] [Abstract][Full Text] [Related]
7. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences.
Greenfield JR; Samaras K; Jenkins AB; Kelly PJ; Spector TD; Gallimore JR; Pepys MB; Campbell LV
Circulation; 2004 Jun; 109(24):3022-8. PubMed ID: 15184288
[TBL] [Abstract][Full Text] [Related]
8. Comparison of soft tissue body composition in postmenopausal women with or without hormone replacement therapy considering the influence of reproductive history and lifestyle.
Dittmar M
Ann Hum Biol; 2001; 28(2):207-21. PubMed ID: 11293728
[TBL] [Abstract][Full Text] [Related]
9. The influence of hormone replacement therapy (HRT) on serum leptin concentration in postmenopausal women.
Hadji P; Görke K; Hars O; Bauer T; Emons G; Schulz KD
Maturitas; 2000 Dec; 37(2):105-11. PubMed ID: 11137329
[TBL] [Abstract][Full Text] [Related]
10. Fat distribution and insulin sensitivity in postmenopausal women: influence of hormone replacement.
Munoz J; Derstine A; Gower BA
Obes Res; 2002 Jun; 10(6):424-31. PubMed ID: 12055317
[TBL] [Abstract][Full Text] [Related]
11. Hormone replacement therapy affects body composition and leptin differently in obese and non-obese postmenopausal women.
Kristensen K; Pedersen SB; Vestergaard P; Mosekilde L; Richelsen B
J Endocrinol; 1999 Oct; 163(1):55-62. PubMed ID: 10495407
[TBL] [Abstract][Full Text] [Related]
12. Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy.
Stauffer BL; Hoetzer GL; Smith DT; DeSouza CA
J Appl Physiol (1985); 2004 Jan; 96(1):143-8. PubMed ID: 12949021
[TBL] [Abstract][Full Text] [Related]
13. Distribution and determinants of C-reactive protein in the older adult population: European Prospective Investigation into Cancer-Norfolk study.
Ahmadi-Abhari S; Luben RN; Wareham NJ; Khaw KT
Eur J Clin Invest; 2013 Sep; 43(9):899-911. PubMed ID: 23786220
[TBL] [Abstract][Full Text] [Related]
14. Impact of hormone replacement therapy on the body mass and fat compositions of menopausal women: a cross-sectional study.
Sayegh RA; Kelly L; Wurtman J; Deitch A; Chelmow D
Menopause; 1999; 6(4):312-5. PubMed ID: 10614678
[TBL] [Abstract][Full Text] [Related]
15. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies.
Keum N; Greenwood DC; Lee DH; Kim R; Aune D; Ju W; Hu FB; Giovannucci EL
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25757865
[TBL] [Abstract][Full Text] [Related]
16. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study.
Feigelson HS; Jonas CR; Teras LR; Thun MJ; Calle EE
Cancer Epidemiol Biomarkers Prev; 2004 Feb; 13(2):220-4. PubMed ID: 14973094
[TBL] [Abstract][Full Text] [Related]
17. The effect of prothrombotic blood abnormalities on risk of deep vein thrombosis in users of hormone replacement therapy: a prospective case-control study.
Douketis JD; Julian JA; Crowther MA; Kearon C; Bates SM; Barone M; Piovella F; Middeldorp S; Prandoni P; Johnston M; Costantini L; Ginsberg JS
Clin Appl Thromb Hemost; 2011; 17(6):E106-13. PubMed ID: 21159708
[TBL] [Abstract][Full Text] [Related]
18. Effect of postmenopause and hormone replacement therapy on serum adiponectin levels.
Sieminska L; Wojciechowska C; Niedziolka D; Marek B; Kos-Kudla B; Kajdaniuk D; Nowak M
Metabolism; 2005 Dec; 54(12):1610-4. PubMed ID: 16311093
[TBL] [Abstract][Full Text] [Related]
19. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: weight and body fat distribution.
Norman RJ; Flight IH; Rees MC
Cochrane Database Syst Rev; 2000; (2):CD001018. PubMed ID: 10796730
[TBL] [Abstract][Full Text] [Related]
20. Plasma fibrinogen levels in healthy postmenopausal women: physical activity and hormone replacement status.
DeSouza CA; Stevenson ET; Davy KP; Jones PP; Seals DR
J Gerontol A Biol Sci Med Sci; 1997 Sep; 52(5):M294-8. PubMed ID: 9310083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
